Skip to content

Debt-to-assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Johnson & Johnson logo
Johnson & JohnsonJNJ
0.3×0.0×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
0.1×0.0×
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
0.0×
AbbVie logo
AbbVieABBV
0.5×0.0×
LBR
LB Pharmaceuticals Inc Common StockLBRX

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M
Total debt$5.6M
Total equity$399.8M+285%
Total assets$418.8M

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K
Free cash flow-$51.2M

Valuation

See full
Market cap$1.39B+100%
Enterprise value$1.34B

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio22.9×

Where this comes from

Calculated from MapLight Therapeutics, Inc. ’s reported figures.

Based on the most recent quarter.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's debt-to-assets?
MapLight Therapeutics, Inc. (MPLT) reported debt-to-assets of 0× in Q1 2026.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.